pentylenetetrazole has been researched along with Autoimmune Diabetes in 1 studies
Pentylenetetrazole: A pharmaceutical agent that displays activity as a central nervous system and respiratory stimulant. It is considered a non-competitive GAMMA-AMINOBUTYRIC ACID antagonist. Pentylenetetrazole has been used experimentally to study seizure phenomenon and to identify pharmaceuticals that may control seizure susceptibility.
pentetrazol : An organic heterobicyclic compound that is 1H-tetrazole in which the hydrogens at positions 1 and 5 are replaced by a pentane-1,5-diyl group. A central and respiratory stimulant, it was formerly used for the treatment of cough and other respiratory tract disorders, cardiovascular disorders including hypotension, and pruritis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yorulmaz, H | 1 |
| Kaptan, E | 1 |
| Seker, FB | 1 |
| Oztas, B | 1 |
1 other study available for pentylenetetrazole and Autoimmune Diabetes
| Article | Year |
|---|---|
Type 1 diabetes exacerbates blood-brain barrier alterations during experimental epileptic seizures in an animal model.
Topics: Animals; Astrocytes; Blood Glucose; Blood Pressure; Blood-Brain Barrier; Convulsants; Cytokines; Dia | 2015 |